3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare shares finished in the red on Friday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) falling 1.11% while the S&P/ASX 200 Index (ASX: XJO) also tumbled 0.5%.

In a recent note, fund manager IML identified three small-cap ASX healthcare shares that it rates a buy.

IML invests in quality companies offering good value now, with the potential for attractive long-term returns and lower volatility than the market average along the way.

Small-cap stocks have a market capitalisation of between a few hundred million dollars to $2 billion. They are smaller up-and-coming companies that are still in growth mode and typically don't pay dividends.

Let's check out the three small-cap ASX healthcare shares that IML has its eye on.

3 ASX healthcare shares tipped for growth

IML Portfolio Manager Marc Whittaker says there are attractive long-term investment opportunities in the small-cap healthcare space.

He has revealed three high-quality ASX stocks "with strong prospects trading at reasonable valuations".

Australian Clinical Labs Ltd (ASX: ACL)

This ASX healthcare share has risen 21% in the year to date and closed at $3.57 on Friday.

Whittaker expects a lift in the share price of this ASX healthcare stock as the pathology provider's performance continues to improve.

He says:

ACL, and many other healthcare stocks, have been suffering from low GP visitation since Covid. We have finally seen GP visitations recover, which has meant more referrals for pathology, but also radiology and other medical tests.

This has directly benefitted ACL which reported that its revenue grew 7 to 8% over the past year and it expects revenue to grow at a similar rate of 5 to 6% next year.

For a company like ACL revenue growth is particularly encouraging because around 70-80% of its costs are fixed, so a significant percentage of increased revenue flows through to profit.

Whittaker says the buyback over the next 12 months "should provide a further boost to its share price".

Regis Healthcare Ltd (ASX: REG)

This ASX healthcare share has risen 97% in the year to date and closed at $6.40 on Friday.

One of Australia's largest aged-care operators, Regis is set to benefit from the Federal Government's proposed new Aged Care Act.

Whittaker says Regis has remained profitable while many other aged care providers have not. Improved government funding and Australia's ageing population are significant tailwinds for the business.

He comments:

Current occupancy for Regis sits at 95%, a level last seen around 2015. Back then its operating margins were over 20%, whereas right now they are at 10.5%.

While it will be difficult for Regis to return to those margin levels – the sector now rightly bears significantly greater compliance, reporting and staffing requirements – we expect its margins to move from the current 10.5% to around 12% to 15% over the next couple of years.

It also has a strong balance sheet, which leaves it well placed to grow through acquisition as we saw recently with its purchase of two new aged care homes.

Integral Diagnostics Ltd (ASX: IDX)

This ASX healthcare share has risen 55% in the year to date and closed at $2.99 on Friday.

As one of Australia's largest diagnostic imaging providers, Integral Diagnostics has faced cost pressures and a lower rate of GP referrals over the past two years.

But Whittaker says things are changing, commenting:

Like ACL, the increase in GP radiology referrals is seeing higher volumes. Additionally, a continued mix shift in radiology work towards higher value and higher margin imaging such as CT and PET scans, as well as higher government indexation on Medicare radiology benefits, allowed IDX to report improved margins in its latest result.

IDX's balance sheet is also improving. Two years ago, it was close to three times net debt to EBITDA and now it is at around two and a half times.

Whittaker is confident the company can continue to grow its revenue at 5% to 8% and reduce its cost growth to about 4% to 5% to increase margins and reduce debt.

He also points out that Integral has a high percentage of fixed costs, so more of the revenue boost would flow through to profits.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »